- Home
- GLDG vs ACRS Comparison
GLDG vs ACRS Comparison
Compare GLDG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDG
- ACRS
- Stock Information
- Founded
- GLDG 2009
- ACRS 2012
- Country
- GLDG Canada
- ACRS United States
- Employees
- GLDG N/A
- ACRS N/A
- Industry
- GLDG Precious Metals
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- GLDG Basic Materials
- ACRS Health Care
- Exchange
- GLDG Nasdaq
- ACRS Nasdaq
- Market Cap
- GLDG 157.0M
- ACRS 127.6M
- IPO Year
- GLDG N/A
- ACRS 2015
- Fundamental
- Price
- GLDG $0.79
- ACRS $1.30
- Analyst Decision
- GLDG Strong Buy
- ACRS Strong Buy
- Analyst Count
- GLDG 1
- ACRS 7
- Target Price
- GLDG $3.25
- ACRS $11.67
- AVG Volume (30 Days)
- GLDG 537.0K
- ACRS 832.4K
- Earning Date
- GLDG 04-11-2025
- ACRS 05-08-2025
- Dividend Yield
- GLDG N/A
- ACRS N/A
- EPS Growth
- GLDG N/A
- ACRS N/A
- EPS
- GLDG N/A
- ACRS N/A
- Revenue
- GLDG N/A
- ACRS $17,777,000.00
- Revenue This Year
- GLDG N/A
- ACRS N/A
- Revenue Next Year
- GLDG N/A
- ACRS $425.96
- P/E Ratio
- GLDG N/A
- ACRS N/A
- Revenue Growth
- GLDG N/A
- ACRS N/A
- 52 Week Low
- GLDG $0.71
- ACRS $0.95
- 52 Week High
- GLDG $1.06
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- GLDG 48.64
- ACRS 43.35
- Support Level
- GLDG $0.75
- ACRS $1.20
- Resistance Level
- GLDG $0.79
- ACRS $1.31
- Average True Range (ATR)
- GLDG 0.03
- ACRS 0.10
- MACD
- GLDG 0.00
- ACRS 0.02
- Stochastic Oscillator
- GLDG 44.50
- ACRS 43.04
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia, Crucero project, located in Peru, Sao Jorge, Batistao, Boa Vista, located in Brazil, Yellowknife Gold Project, located in the Northwest Territories, Canada, and other projects. The company earns maximum revenue from Canada.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.